CD274 and non-small cell lung carcinoma: The Tissue Insight 22C3 PDL1 NSCLC DA fulfilled these criteria and was clinically validated (i.e. according to CLIA standards of sensitivity, specificity, accuracy and precision) supporting its adoption as a predictor of checkpoint inhibitor therapy and future use in clinical trials.